Abstract 166P
Background
Schwann cells (SCs) are a type of peripheral nerve system(PNS) glial cell that support the viability of myelinated and unmyelinated peripheral nerve fibers. Our previous studies identified SCs in human lung cancer specimens and demonstrated that SCs could increase the metastasis of lung cancer by activating the PI3K/AKT/GSK-3b/Snail-7wist signaling pathway and enhancing M2 macrophage polarization via CCL2 secretion. However, in the lung cancer mouse model, complete identification of airway nerves (or other cellular/subcellular objects) has not been possible due to patchy distribution and micron-scale size.
Methods
In this study, we describe a method using tissue clearing to acquire the first complete image of three-dimensional (3D) innervation in lung cancer. Mouse airways were harvested from the Metastatic tumor model of C57BI/6 mice and separated from the heart. The tissues were dehydrated, rehydrated and completely transparented. The specimens were labeled for the pan-neuronal marker PGP9.5 with a mouse antibody. All images were acquired using a confocal microscope. 3D images of fluorescently casted airways were processed to make airway masks. To quantify visceral pleural nerve distribution in mice, nerves were modeled using computer tractography and measured in different lung cancer regions.
Results
We found that nerves are widely distributed in both lung and lung tissues. The shape of peripheral nerves is similar to blood vessels, showing reticular shape along the bronchi and bronchioles. However, the distribution of peripheral nerves in the lung has not changed due to lung cancer. Interestingly and critically, the fluorescence intensity of the nerve near the side of lung cancer is much stronger, suggesting that the phenotype of peripheral nerves may change after interaction with lung cancer cells. The nerve growth in lung cancer tissue is abundant and active.
Conclusions
We first complete the image of three-dimensional (3D) innervation in lung cancer. The interaction between peripheral nerves and lung cancer may affect the phenotype of peripheral nerves and thus regulate the malignant biological course of lung cancer. PNS may play an oncogenic role in lung tumor progression and may serve as a therapeutic target for further analysis.
Legal entity responsible for the study
Shanghai Chest Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma compared to patients with advanced solid tumours
Presenter: Ciro Celsa
Session: Poster Display
112P - Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Presenter: Danielle Delombaerde
Session: Poster Display
113P - A multidisciplinary management of immune-checkpoint inhibitor (ICI)-related pneumonitis to improve its clinical management
Presenter: Monica Valente
Session: Poster Display
114P - Real-World Insights on Pan-Cancer Immune Checkpoint Inhibitor Treatment: Initial Findings of a Belgian Multicenter Study
Presenter: Annelies Verbiest
Session: Poster Display
115TiP - MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC
Presenter: Martin Reck
Session: Poster Display
117TiP - BGB-HNSCC-201 (NCT05909904): Phase 2, Open-Label, Multi-Arm, Global Study of Tislelizumab (TIS) + Investigational Agents as First-Line (1L) Treatment in Patients (Pts) With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Presenter: Kevin Harrington
Session: Poster Display
121P - MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) With/Without Docetaxel in Metastatic NSCLC After Platinum-Chemotherapy (Chemo) and Immunotherapy
Presenter: Nir Peled
Session: Poster Display
123P - A phase II study of nivolumab (N) plus ipilimumab (I) and ASTX727 or N plus I in PD-1/PD-L1 resistant melanoma or NSCLC patients: the run-in phase of the NIBIT Foundation ML1 Study
Presenter: Anna Di Giacomo
Session: Poster Display
124P - Surufatinib plus toripalimab combined with etoposide (E) and cisplatin (P) in patients (pts) with advanced naive small cell lung cancer (SCLC) -Updated results of a phase ?b/? trial
Presenter: Wen Feng Fang
Session: Poster Display